No influence of the P-glycoprotein polymorphisms MDRI G2677T/A and C3435T on the virological and immunological response in treatment naïve HIV-positive patients

Annals of Clinical Microbiology and Antimicrobials

Volumn 4, Issue , 2005, Pages

  Winzer, Ralf ^a   Langmann, Peter ^a   Zilly, Michael ^a   Tollmann, Franz ^a   Schubert, Jörg ^a   Klinker, Hartwig ^a   Weissbrich, Benedikt ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOLLOW UP; GENOTYPE; HAPLOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; PROTEIN POLYMORPHISM; RETROSPECTIVE STUDY; CD4 LYMPHOCYTE COUNT; GENE; GENETIC POLYMORPHISM; IMMUNOLOGY; MIDDLE AGED; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; GENES, MDR; GENOTYPE; HIV SEROPOSITIVITY; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; VIRAL LOAD;

EID: 23144442403     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-4-3     Document Type: Article

References (25)

1. Srinivas RV, Middlemas D, Flynn P, Fridland A: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 1998, 42:3157-3162.
2. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427.
3. Chaudhary PM, Mechetner EB, Roninson IB: Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood 1992, 80:2735-2739.
4. Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, DeYoung J, Taylor T, Carlson EJ, Herskowitz I, Giacomini KM, Clard AG: Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003, 13:481-494.
5. Sakaeda T, Nakamura T, Okumura K: MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002, 25:1391-1400.
6. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004, 75:13-33.
7. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, Swiss HIV Cohort Study: Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 2002, 359:30-36.
8. Pallis M, Russell N: P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 2000, 95:2897-2904.
9. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW: The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis. Proc Natl Acad Sci U S A 1998, 95:7024-7029.
10. Weisburg JH, Roepe PD, Dzekunov S, Scheinberg DA: Intracellular pH and multidrug resistance regulate complement-mediated cytotoxicity of nucleated human cells. J Biol Chem 1999, 274:10877-10888.
11. Lee CGL, Ramachandra M, Jeang KT, Martin MA, Pastan I, Gottesmann MM: Effect of ABC transporters on HIV-1 infection:inhibition of virus production by the MDR1 transporter. FASEB J 2000, 14:516-522.
12. Speck RR, Yu XF, Hildreth J, Flexner C: Differential Effects of P-Glycoprotein and Multidrug Resistance Protein-1 on Productive Human Immunodeficiency Virus Infection. J Infect Dis 2002, 186:332-340.
13. Bleiber G, May M, Suarez C, Martinez R, Marzolini C, Egger M, Telenti A, Swiss HIV Cohort Study: MDR1 Genetic Polymorphism Does Not Modify either Cell Permissiveness to HIV-1 or Disease Progression before Treatment. J Infect Dis 2004, 189:583-586.
14. Langmann P, Klinker H, Schirmer D, Zilly M, Bienert A, Richter E: High-performance liquid chromatographic method for the simultaneous determination of HIV-1 protease inhibitors indinavir, saquinavir and ritonavir in plasma of patients during highly active antiretroviral therapy. J Chromatogr B Biomed Sci Appl 1999, 735:41-50.
15. Langmann P, Schirmer D, Vath T, Zilly M, Klinker H: High-performance liquid chromatographic method for the determination of HIV-1 non-nucleoside reverse transcriptase inhibitor efavirenz in plasma of patients during highly active antiretroviral therapy. J Chromatogr B Biomed Sci Appl 2001, 755:151-156.
16. The European AIDS Clinical Society Euroguidelines Group: European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003, 17(Suppl 2):S3-S26.
17. Winzer R, Langmann P, Zilly M, Tollmann F, Schubert J, Klinker H Weissbrich B: No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment. Eur J Med Res 2003, 8:531-534.
18. Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I: Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 2004, 334:201-203.
19. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini C, Esposito R, Cossarizza A: MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS 2003, 17:1696-1698.
20. Petersen C, Pun E, Myrand S, Lin C, Paulauskis J, Bleavins M, Johnson S, Daniels E, Haubrich R: Allelic Variants of MDR1, CYP2C19, and CYP3A5: Distribution and Associations in Patients Receiving Nelfinavir or Efavirenz-containing HAART [abstract]. CROI 10th 2003 [http://www.retroconference.org/2003/cd/Abstract/575.htm]. abstract 575
21. Sparreboom A, Danesi R, Ando Y, Chan J, Figg W: Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Resist Updat 2003, 6:71-84.
22. Shen LX, Basilion JP, Stanton VP Jr: Singlenucleotide polymorphisms can cause different structural folds of mRNA. Proc Natl Acad Sci U S A 1999, 96:7871-7876.
23. Frittitta L, Ercolino T, Bozzali M, Argiolas A, Graci S, Santagati MG, Spampinato D, Di Paola R, Cisternino C, Tassi V, Vigneri R, Pizzuti A, Trischitta V: A cluster of three single nucleotide polymorphisms in the 3′-untranslated region of human glycoprotein PC-1 gene stabilizes PC-1 mRNA and is associated with increased PC-1 protein content and insulin resistance-related abnormalities. Diabetes 2001, 50:1952-1955.
24. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB: MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection. J Acquir Immune Defic Syndr 2003, 34:295-298.
25. Brumme ZL, Donga WWY, Chana KJ, Hogga RS, Montanera JSG, O'Shaughnessya MV, Harrigana PR: Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 2003, 17:201-208.